Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assay.

Chimeric antigen receptor (CAR)-T cell therapies reprogram T cells to engage and eliminate cancer cells. Patients' T cells are transduced using lentiviral or retroviral vectors containing a CAR transgene. Following infusion, CAR-T cells expand and may persist in the peripheral blood and bone marrow for years.